Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

I-Mab ADR (NQ: IMAB )

0.9397 -0.0003 (-0.03%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 466
Open 0.9397
Bid (Size) 0.9300 (22)
Ask (Size) 0.9400 (17)
Prev. Close 0.9400
Today's Range 0.9397 - 0.9397
52wk Range 0.8989 - 2.536
Shares Outstanding 185,613,662
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Week In Review: Zenas Raises $259 Million In IPO
It was a quiet week for biotech news in the Chinese market. Here is a brief overview of the notable events that occurred during this time. Zenas BioPharma staged a rare US biopharma IPO worth $259... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market

Performance

YTD
-58.24%
-58.24%
1 Month
-20.36%
-20.36%
3 Month
-27.72%
-27.72%
6 Month
-45.99%
-45.99%
1 Year
-38.58%
-38.58%

More News

Read More
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
Via Talk Markets
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
(IMAB) - Analyzing I-MAB's Short Interest
Via Benzinga
Looking Into I-MAB's Recent Short Interest
Via Benzinga
Expert Ratings for I-MAB
Via Benzinga
Where I-MAB Stands With Analysts
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million
Via Talk Markets
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Analyst Ratings for I-MAB
Via Benzinga
5 Analysts Have This to Say About I-MAB
Via Benzinga
I-Mab Reveals Promising Results in Phase 1b/2 Study for Advanced Non-Small Cell Lung Cancer Treatment
Via Benzinga
Week In Review: Two China Biopharmas Announce Billion Dollar Deals
Via Talk Markets
Week In Review: Adlai Nortye Stages $97.5 Million US IPO On Nasdaq
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Week In Review: GenFleet Out-Licenses Three Candidates To Verastem In $625 Million Deal
Via Talk Markets
7 F-Rated Biotech Stocks You Shouldn’t Touch With a 10-Foot Pole
Via InvestorPlace
Why Is TRACON Pharma (TCON) Stock Down 51% Today?
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Last Day Of Q1
Via Benzinga
ImmuneOnco Banks On Cutting-edge Cancer Drugs To Attract IPO Cash
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.